Literature DB >> 19141395

Immunohistochemical analysis of MMP-9, MMP-2 and TIMP-1, TIMP-2 expression in the central nervous system following infection with viral and bacterial meningitis.

Artur Sulik1, Lech Chyczewski.   

Abstract

Matrix metalloproteinases (MMPs) are capable of degrading components of the basal lamina of cerebral vessels, thereby disrupting the blood-brain barrier and inducing leukocyte recruitment. This study provides comprehensive information regarding the cell specificity of matrix metalloproteinases (MMP-2, MMP-9) and their binding tissue inhibitors (TIMP-1, TIMP-2) in the central nervous system during viral and bacterial meningitis. Specifically, we evaluated the immunoreactivity of MMPs and TIMPs in various cell types in brain parenchyma and meninges obtained from autopsy tissues. We found that a higher proportion of endothelial cells were positive for MMP-9 during meningitis when compared to controls. In addition, the immunoreactivity of MMP-9 decreased and the immunoreactivity of TIMP-1 increased in astrocytes upon infection. Furthermore, the results of this study revealed that mononuclear cells were highly immunoreactive for TIMP-1, TIMP-2 and MMP-9 during viral meningitis and that the expression of TIMPs in polymorphonuclear cells was even higher during bacterial meningitis. Taken together the results of this study indicated that the central nervous system resident cells and inflammatory infiltrates contribute to MMPs activity and that the expression patterns vary between cell types and in response to viral and bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19141395     DOI: 10.2478/v10042-008-0058-8

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  7 in total

Review 1.  Fetal hypoxia and programming of matrix metalloproteinases.

Authors:  Wenni Tong; Lubo Zhang
Journal:  Drug Discov Today       Date:  2011-09-18       Impact factor: 7.851

Review 2.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Maternal hypoxia increases the activity of MMPs and decreases the expression of TIMPs in the brain of neonatal rats.

Authors:  Wenni Tong; Wanqiu Chen; Robert P Ostrowski; Qingyi Ma; Rhonda Souvenir; Lubo Zhang; John H Zhang; Jiping Tang
Journal:  Dev Neurobiol       Date:  2010-02-15       Impact factor: 3.964

4.  Expression of osteopontin, matrix metalloproteinase-2 and -9 proteins in vascular instability in brain arteriovenous malformation.

Authors:  Lalita Anbarasen; Jasmine Lim; Retnagowri Rajandram; Kein Seong Mun; Sheau Fung Sia
Journal:  PeerJ       Date:  2019-06-24       Impact factor: 2.984

5.  IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.

Authors:  Matthew N Svalina; Ken Kikuchi; Jinu Abraham; Sangeet Lal; Monika A Davare; Teagan P Settelmeyer; Michael C Young; Jennifer L Peckham; Yoon-Jae Cho; Joel E Michalek; Brian S Hernandez; Noah E Berlow; Melanie Jackson; Daniel J Guillaume; Nathan R Selden; Darell D Bigner; Kellie J Nazemi; Sarah C Green; Christopher L Corless; Sakir Gultekin; Atiya Mansoor; Brian P Rubin; Randall Woltjer; Charles Keller
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

Review 6.  The Potentials of Melatonin in the Prevention and Treatment of Bacterial Meningitis Disease.

Authors:  Dong Zhang; Shu Xu; Yiting Wang; Guoqiang Zhu
Journal:  Molecules       Date:  2021-03-05       Impact factor: 4.411

7.  Burkholderia pseudomallei pathogenesis in human skin fibroblasts: A Bsa type III secretion system is involved in the invasion, multinucleated giant cell formation, and cellular damage.

Authors:  Anek Kaewpan; Taksaon Duangurai; Amporn Rungruengkitkun; Watcharamat Muangkaew; Tapanee Kanjanapruthipong; Niramol Jitprasutwit; Sumate Ampawong; Passanesh Sukphopetch; Narisara Chantratita; Pornpan Pumirat
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.